National Cohort of Subjects at Risk of Developing Rheumatoid Arthritis

PROMESS 1 is a multicenter cohort interventional study aiming at analyzing the factors associated with the risk of developing clinical arthritis among exposures or combinations of exposures in patients at risk of rheumatoid arthritis (RA), as they have high levels of anti-citrullinated peptides autoantibodies (ACPA ≥2 N). The primary endpoint is the occurrence of clinical arthritis confirmed by ultrasound at two years of following for the subject's groups at risk of RA. This may be explained by the following exposures or combinations of exposures: smoking, occupational exposure, physical activity, diet, hormonal exposure, drug exposure, trauma and psychological stress. Other factors may also explain the occurrence of clinical arthritis: * Other symptoms * Comorbidities, medical history, drug exposures * Current biology: ACPA levels, rheumatoid factor levels and isotypes, CRP levels at baseline, etc. * Ultrasound and MRI abnormalities.

NCT Number	NCT06876064
Lead Sponsor	University Hospital, Montpellier Collaborators: Nantes University Hospital, Assistance Publique Hopitaux De Marseille, University of New Orleans, Bicetre Hospital, Saint Antoine University Hospital, Groupe Hospitalier Pitie-Salpetriere, University Hospital, Brest, Assistance Publique - Hôpitaux de Paris, University Hospital, Bordeaux, Hôpital Cochin
Conditions	Rheumatoid Arthritis (RA)
Enrollment	150 participants
Start Date	2025-10
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-10-01